NDA 021778 · Endo Operations
Megace Es
Megestrol Acetate · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Dec 18, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Jul 5, 2005
Approved uses
1
Original approval plus efficacy supplements
Registered trials
122
40 Phase 3, 22 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- MEGACE ES · MEGESTROL ACETATE 125MG/ML · SUSPENSION, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Megestrol" as an intervention, any sponsor and status, largest first.
University College, LondonAcademic, hospital or other
NCT07831902 · 600 participants (planned) · Start Jun 29, 2026 · Primary completion Dec 2030
Drug: medroxyprogesterone acetate tablets OR megestrol acetate; Cisplatin and 1 more · For: Endometrial Cancer; Uterine Neoplasms
Sites: Bath, United Kingdom; Cheltenham, United Kingdom; Leicester, United Kingdom · 12 sites in all
- Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01035229 · 546 participants · Start Apr 2010 · Primary completion Oct 2013
Drug: Everolimus; Everolimus Placebo · For: Carcinoma
Sites: Fayetteville, Arkansas; Fountain Valley, California; La Jolla, California · 131 sites in all
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT07243379 · 495 participants (planned) · Start Sep 25, 2025 · Primary completion Dec 31, 2026
Drug: Nanocrystalline Megestrol Acetate · For: Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia; Multicenter Observational Study
Sites: Zhengzhou, China
- Comparison of Megestrol and/or Omega-3 Fatty Acid-Enriched Nutritional Supplement in Treating Patients With Cancer-Related Weight Loss and Lack of AppetitePivotal-lookingCompleted
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT00031707 · 429 participants · Start Mar 2000 · Primary completion Jan 2004
Drug: megestrol acetate · For: Anorexia; Cachexia
Sites: Scottsdale, Arizona; Jacksonville, Florida; Peoria, Illinois · 44 sites in all
- Nutrition Impact on Immunotherapy of CancerPivotal-lookingRecruiting
Qingdao Central HospitalAcademic, hospital or other
NCT06500234 · 300 participants (planned) · Start Jun 1, 2024 · Primary completion May 31, 2025
Drug: Megestrol Acetate and olanzapine; Starch powder 50 mg · For: Nutrition Disorders; Immunotherapy; Cancer and 1 more
Sites: Qingdao, China
- Megestrol in Treating Patients With Liver Cancer That Cannot Be Removed By SurgeryPivotal-lookingCompleted
National Medical Research Council (NMRC), SingaporeGovernment (non-federal)
NCT00041275 · 300 participants (planned) · Start May 2002 · Primary completion Jun 2007
Drug: megestrol acetate · For: Liver Cancer
Sites: Dhaka, Bangladesh; Yangon, Burma; Denpasar, Indonesia · 12 sites in all
- S9626: Megestrol in Treating Hot Flashes Following Treatment for Breast CancerPivotal-lookingCompleted
SWOG Cancer Research NetworkResearch network
NCT00005975 · 288 participants · Start Apr 1998 · Primary completion Sep 2001
Drug: Megestrol Acetate 20mg/day; Megestrol Acetate 40 mg/day and 2 more · For: Breast Cancer; Hot Flashes
- Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular ClassificationPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT07319429 · 260 participants (planned) · Start Jan 25, 2026 · Primary completion Dec 31, 2027
Drug: PD1 antibody; Medroxyprogesterone Acetate 500 MG and 2 more · For: Endometrial Cancer; Fertility
Sites: Shanghai, China · 2 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Megestrol acetate.
Canetta R, Florentine S, Hunter H, et al. · Cancer Treat Rev 1983 · Clinical Trial, Review
- Association of Hormonal Contraceptive Use With Adverse Health Outcomes: An Umbrella Review of Meta-analyses of Randomized Clinical Trials and Cohort Studies.
Brabaharan S, Veettil SK, Kaiser JE, et al. · JAMA Netw Open 2022 · Systematic Review
- Management of Androgen Deprivation Therapy-Associated Hot Flashes in Men With Prostate Cancer.
Qan'ir Y, DeDeaux D, Godley PA, et al. · Oncol Nurs Forum 2019 · Research Support, Non-U.S. Gov't, Systematic Review
- Oncological outcomes in fertility-sparing treatment in stage IA-G2 endometrial cancer.
Ronsini C, Mosca L, Iavarone I, et al. · Front Oncol 2022 · Systematic Review
- Systematic review and meta-analysis of cannabinoids in palliative medicine.
Mücke M, Weier M, Carter C, et al. · J Cachexia Sarcopenia Muscle 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
- HIV-related weight loss.
· PI Perspect 1997 · Clinical Trial, Controlled Clinical Trial
Sponsor: Endo Operations
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.